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Abstract - Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide with a high mortality. Immu-
nohistochemical overexpression of the p53 protein was correlated with a poor prognosis in various human malignancies, 
including HCC. In our study, 45 resected HCCs were examined to evaluate the expression of p53 and its correlation with 
clinicopathological parameters. Immunohistochemical detection of  p53 with monoclonal human antibody, revealed its 
overexpression in 20 tumors (44%), including diffuse positive in 7 cases (35%), heterogeneous in 5 (25%), and focal in 8 
(40%). We considered a positive reaction only in the presence of immunostained nuclei in brown shades in more than 5% 
of the tumor nuclei. To elucidate the significance of p53 in HCC, we correlated its protein expression with major clini-
copathological features. We did not observe significant correlation with sex, age, presence of cirrhosis, chronic hepatitis 
status, tumoral necrosis and tumor size. The density and intensity of p53 revealed significant correlation with histological 
grade (P=0.008 and P=0.014) and tumor stage (P=0.005 and P=0.007). In conclusion, our results suggest that overexpres-
sion of p53 is associated with HCC progression and contributes to disease progression. Moreover, p53 expression may be 
a valuable marker of HCC prognosis. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the 
most  frequent  cancers  worldwide,  with  high 
risk in Asia and Africa and less common, but 
with increasing incidence, in Western developed 
countries (Stefan et al., 1992). The mortality in 
HCC is increased, with an estimated number of 
1 million deaths annually and a survival rate less 
than 5% for 5 years (Ahmad et al. 2007; Blum et 
al. 2007). 
In  recent  years,  research  has  focused  on  the 
identification of prognosis markers in order to fa-
cilitate the early detection of HCC and to guide the 
development of targeted therapy. Strachan and Read 
(1999) described as p53 as “the guardian of the ge-
nome” due to its important role in preserving stabil-
ity by preventing genome mutation. Mutation of the 
p53 suppressor gene is the most commonly detected 
anomaly in human cancers (Shuang-Jian et al., 1998; 
Yun  et  al.,  1998).  Immunohistochemical  overex-
pression of p53 protein was correlated with a poor 
prognosis in various human malignancies including 
HCC (Qin et al., 2001; Hsia et al., 2000).
The purpose of our study was to evaluate the sig-
nificance of p53 protein immunoreactivity in HCC 
and to determine whether p53 reactivity correlates 
with conventional parameters of prognosis.842 ANDREEA CIOCA ET AL.
MATERIALS AND METHODS
Forty-five patients with HCC who had undergone 
hepatic resection were selected for this retrospec-
tive  study.  The  clinicopathological  data  including 
sex, age, tumor necrosis, histological grading, tumor 
stage, hepatitic status, the presence of cirrhosis and 
tumor size. 
Specimens  were  fixed  in  10%  buffer  formalin 
and paraffin-embedded. In order to assess the tu-
mor grade and stage, histological sections were cut 
at 5-μm thickness and stained using the hematoxylin 
and eosin method. 
For immunostaining, p53 was used a primary an-
tibody. We performed heat-induced epitope retrieval 
with  a  citrate-based  pH  6.0  solution  (Novocastra, 
Newcastle uponTyne, UK) for 30 min. Endogenous 
peroxidase blocking was realized with 3% hydrogen 
peroxide for 5 min. This step was followed by incuba-
tion for 30 min with p53 (Bond ready to use primary 
antibody, clone DO-7, Leica Biosystems, Newcastle 
uponTyne, UK). The Bond Polymer Refine Detection 
System (Leica Biosystems, Newcastle uponTyne, UK) 
was used for visualization. 3,3 diaminobenzidine di-
hydrochloride was applied as chromogen, and hema-
toxylin was used for counterstaining. The entire im-
munohistochemical procedure was performed with 
Leica Bond-Max (Leica Biosystems, Newcastle upon 
Tyne, UK) autostainer.
Three  independent  microscopic  fields  (×400) 
were selected for each sample and all the tumor cells 
within each microscopic field were counted, and then 
the positive percent of p53 cells was calculated. We 
considered a positive reaction only in the presence 
of immunostained nuclei in brown shades, in more 
than 5% of the tumoral nuclei. Three staining pat-
terns were recognized: diffuse nuclear staining that 
expressed uniform diffuse positivity on tumoral cells 
(>50%,  Fig.1),  heterogenous  nuclear  staining  that 
expressed areas of strong positivity alternating with 
areas of weak positivity (10%-50%) and focal nuclear 
staining that expressed small nests or isolated tumor-
al cells (>5%, Fig.2). 
The intensity of reaction was assessed as low (+), 
moderate (++) or intense (+++).
Examination was performed with an Eclipse E80i 
Nikon microscope and images were acquired with 
Lucia G software for microscopic image analysis.
Statistical analysis was performed using the com-
mercially available SPSS version 17.0. We applied the 
Student’s t-test and p-values of less than 0.05 values 
were considered significant.
RESULTS
Our  study  included  samples  from  45  patients  (32 
males and 13 females), aged between 29-77 years. In 
relation to tumor size, HCCs were divided into 2 cat-
egories: tumors smaller than 5 cm and tumors greater 
than 5 cm. From the 45 HCCs, 12 tumors were larger 
than 5 cm and 33 were smaller than 5 cm. Accord-
ing to the Edmondson and Steiner system (Edmond-
son et al., 1954), tumor grade was divided into three 
groups: well differentiated (grade I-4 cases), mod-
erately differentiated (grade II-20 cases) and poorly 
differentiated (grades III and IV-21 cases). Histologi-
cally, most of the HCCs showed a trabecular pattern 
admixed with a pseudoglandular pattern (23 cases) 
or with a solid pattern (9 cases). Tumor stages were 
classified as I (12 cases), II (18 cases), III (14 cases), 
and IV (1 case). The nontumorous liver showed cir-
rhosis in 17 (38%) patients and chronic hepatitis in 
18 (40%).
The main clinicopathological features of patients 
investigated and the correlations with p53 are pre-
sented in Table 1.
By immunohistochemical stain, the p53 protein 
was detected in the tumor cell nucleus in 20 HCCs 
(44%), including focal positive in 8 cases (40%) (Fig. 
1A), diffuse positive in 7 (35%) cases (Fig. 1B), with 
heterogeneous pattern in 5 (25%) cases (Fig. 1C). 
Those without p53 expression or positive p53 expres-
sion in less than 5% of tumor cells were considered 
as negative (25 cases, 56%). From all of the 45 HCCs, 
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in 8 (40%) cases (Fig. 1D), moderate positivity in 7 
(35%) cases and weak positivity in 5 (25%) cases. 
Clinicopathological data including sex, age, pres-
ence of cirrhosis, chronic hepatitis, tumor stage, his-
tological grading, tumor size and presence of tumoral 
necrosis. P53 expression showed positivity in 43.7% 
of males and 46.1% of females and appeared to be 
more frequently in young patients (53.8% in patients 
<60 years and 40.6% in patients >60 years).
Table 1.
Clinicopathological parameters No. of cases P53 positive cases (%)
P53 density
p-value
P53 intensity
p-value
Gender
Males 32 14 (43.7%) >0.5 >0.5
Females 13 6 (46.1%) >0.5 >0.5
Age
<60 years 13 7 (58.8%) >0.5 >0.5
>60 years 32 13 (40.6%) >0.5 >0.5
Grade
Well differentiated (gr. I) 4 0
0.008 0.014 Moderately differentiated (gr. II) 20 7 (35%)
Poorly differentiated (gr. III, IV) 21 13 (62%)
Stage
I 12 4 (33%)
0.05 0.07
II 18 11 (61%)
III (A, B, C) 14 5 (36%)
IV 1 0 (0%)
Tumor size
<5cm 33 14 (42%)
>0.5
>5 cm 12 6 (50%)
Tumoral necrosis 17 7 (41%) >0.5
Cirrhosis 17 8 (47%) >0.5
Chronic hepatitis 18 8 (44%) >0.5
Fig. 1. Distribution patterns and intensity of p53 expression in HCC. Focal expression of p53 in HCC (A) compared with its diffuse 
expression (B). Heterogenous expression of p53 intensity in different tumor cells nuclei (C). Note the homogeneous expression in other 
cases with the same intensity in almost all nuclei (D).844 ANDREEA CIOCA ET AL.
Regarding  tumor  stage,  the  expression  of  p53 
presented a maximum score in stage II (61%) and 
stage III (38%). A significant correlation was noted 
between  overexpression  of  p53  and  tumoral  stage 
(P=0.005). As shown in Table 1, p53 protein expres-
sion tended to occur in HCCs with high grade (grade 
II-IV; P=0.008). 
P53 showed positivity in 12 (50%) HCCs larg-
er than 5 cm and in 33 (42%) HCCs smaller than 
5 cm. We analyzed the relation of p53 with tumor 
size, which is known as an important prognostic fac-
tor in HCC, but the correlation was not significant 
(P>0.5). 
P53 immunoreactions did not exhibit a relation 
with the other clinicopathological parameters. 
DISCUSSION
The tumor-suppressor gene p53, which is located on 
the short arm of chromosome17, plays an essential 
role  in  preserving  stability  by  preventing  genome 
mutation. The major function of the gene is to block 
cell cycle progression in response to DNA damage 
(Cornelia et al., 2009). Wild-type p53 (wt) is at low 
levels in normal tissue and usually it cannot be de-
tected with immunohistochemical stains. Unlike wt 
p53 protein, mutant forms are more stable and have 
a prolonged half-life, which favors intranuclear ac-
cumulation,  becoming  detectable  immunohisto-
chemically (Steele et al. 1998). In several studies, the 
overexpression of p53 in the serum or liver tissues 
of HCC patients was associated with poorer progno-
sis and a shorter survival time (Cornelia et al., 2009; 
Zhou et al., 2006; Liu el al., 2012). 
In recent years, many studies explored the ex-
pression and the mutations of p53 in HCC and the 
results are various. Caruso et al. (1999), studied the 
immunohistochemical expression in a series of 193 
HCC  specimens,  and  overexpression  of  p53  was 
observed in only 29 (15%) HCCs, frequently in tu-
mors with poor cellular differentiation, but without 
reaching statistical significance. In the study of Ng et 
al. (1995), overexpression of p53 was found in 31% 
HCCs and unlike the results of the study conducted 
by Caruso et al. (1999) here a significant correlation 
between p53 overexpression and the poor cellular 
differentiation was found. Zhao et al. (1994) analyzed 
p53 immunoreactivity using five anti-p53 protein an-
tibodies and the results ranged from 67.5% to 10.8%, 
which strongly suggests that the immunoreactivity 
of p53 is influenced by the antibody used. Moreover, 
the results may vary depending on the geographical 
area, being lower in Europe where exposure to afla-
toxin B1 does not occur (Boix-Ferrero et al. 1999). In 
our research, immunohistochemical analysis of p53 
demonstrated  accumulation  of  nuclear  staining  in 
44% of cases, which is consistent with the results of 
Boix-Ferrero et al. (1999).
Several studies found that overexpression of p53 
does not correlate with p53 mutation in HCC (Hsia 
et al., 2000; Boix-Ferrero et al., 1999; Anzola et al., 
2004). An explanation could be the presence of other 
factors that might contribute to the inactivation of 
the p53 rather than mutations, such as viral proteins 
(Boix-Ferrero et al., 1999; Bourdon et al., 1995). Kang 
et al. (1998) compared overexpression and mutation 
of p53 in HCC and found that 50% of cases showed 
positivity for p53 but mutations were detected in only 
25% cases. In the same study, p53 protein was positive 
in high-grade dysplastic nodules but none had muta-
tions in the exons examined (Kang et al., 1998).
Our study showed that p53 overexpression was 
significantly associated with the poor histological dif-
ferentiation of tumor cells (P=0.008), which is con-
sistent with previous reports (Qin et al., 2001; Caruso 
et al., 1999; Ng el al., 1995; Sung et al., 2005; Hsu et 
al. 1993; Lee et al., 2002). Moreover, we found signifi-
cant correlation with tumoral stage (P=0.005), which 
is known to be an independent prognosis factor. 
CONCLUSIONS
The immunohistochemical expression of p53 in 45 
patients with HCC showed a positive reaction in 44% 
of cases. We found a significant statistic correlation 
between p53 expression and tumoral stage and grade. 
Our results suggest that the overexpression of p53 is P53 EXPRESSION AS A PROGNOSTIC MARKER IN HEPATOCELLULAR CARCINOMA 845
associated with HCC progression. We conclude that 
the p53 protein has an important role in hepatocar-
cinogenesis and contributes to a poor prognostic in-
directly by grade and tumor stage.
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